

## Ansuvimab

## Chemical Properties

CAS No. : 2375952-29-5

Formula:

Molecular Weight:

Storage: Store at low temperature  
Store at -20°C

Actual storage temperature shall be subject to the COA.

## Biological Description

Description	Ansuvimab is a humanizing neutralizing monoclonal antibody targeting the glycoprotein (GP) of Zaire ebolavirus (EBOV). The antibody specifically binds to a highly conserved epitope (LEIKKPDGS) within the receptor-binding site of the EBOV GP1 subunit, effectively blocking the interaction between the viral glycoprotein and the host intracellular Niemann-Pick C1 (NPC1) receptor. In addition to its neutralizing activity, Ansuvimab mediates antibody-dependent cellular cytotoxicity (ADCC) to facilitate the clearance of infected cells by the immune system. As the first approved treatment for Ebola virus infection, it possesses significant clinical value in reducing viral load and improving patient survival rates.
Targets(IC50)	Virus Protease
In vitro	In biochemical assays, Ansuvimab targets the GP1 subunit of the Ebola virus glycoprotein, specifically binding the LEIKKPDGS epitope to prevent interaction with the NPC1 receptor. In cell-based models, Ansuvimab exhibits potent antibody-dependent cellular cytotoxicity (ADCC) against GP-expressing target cells, with activity plateauing at approximately 0.03 µg/mL [2].
In vivo	In non-human primate (macaque) infection models, Ansuvimab demonstrates remarkable therapeutic efficacy. A pivotal study showed that even when treatment was initiated 5 days post-infection, a single dose of Ansuvimab resulted in 100% survival of animals exposed to a lethal dose of Ebola virus, highlighting its substantial therapeutic window and potent viral neutralization capacity [2].

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481